Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer

Background: Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line setting of untreated advanced ALK-positive NSCLC and in the second-line setting of crizotinib-resistant ALK-positive NSCLC. Despite promising efficacy and tolerability in the treatment of advanced ALK-pos...

Full description

Bibliographic Details
Main Authors:	Yan Hu, Siying Ren, Ruoyao Wang, Wei Han, Peng Xiao, Li Wang, Fenglei Yu, Wenliang Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Pharmacology
Subjects:	pathological complete response neoadjuvant therapy alectinib ALK non-small cell lung cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.816683/full

Similar Items

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
by: Liang Shi, et al.
Published: (2023-06-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
by: Peijun Cao, et al.
Published: (2023-08-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
by: Justin M. Cheung, MD, et al.
Published: (2024-03-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
by: Zihua Zou, et al.
Published: (2022-01-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
by: Caicun Zhou, MD, PhD, et al.
Published: (2024-09-01)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
by: Lucheng Zhu, et al.
Published: (2022-11-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
by: Yurong Wang, et al.
Published: (2022-12-01)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
by: Chuangzhou Rao, et al.
Published: (2022-09-01)

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report
by: Chloe Weidenbaum, DO, et al.
Published: (2022-08-01)

Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor
by: Roberto Ravasio, et al.
Published: (2022-10-01)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
by: Deng Ling, et al.
Published: (2022-08-01)

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib
by: Xiaoqian Zhai, et al.
Published: (2023-03-01)

Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC
by: Lianxi Song, MD, et al.
Published: (2024-12-01)

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review
by: Pei Li, et al.
Published: (2024-02-01)

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
by: Yanyan Qin, et al.
Published: (2022-12-01)

A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement
by: Yang Zheng, et al.
Published: (2024-07-01)

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer
by: Sulim Kang, et al.
Published: (2022-05-01)

Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report
by: Robina Aerts, et al.
Published: (2022-09-01)

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report
by: Yingying Zhu, et al.
Published: (2020-07-01)

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
by: Hongxia Wang, et al.
Published: (2025-01-01)

Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
by: Lingxin Yan, et al.
Published: (2023-08-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
by: Ritsuko Nakai, et al.
Published: (2019-12-01)

Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report
by: Kei Kunimasa, et al.
Published: (2024-12-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
by: Xu Feng, et al.
Published: (2021-06-01)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
by: Yuri Isaka, et al.
Published: (2023-01-01)

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
by: Dong-Wan Kim, MD, PhD, et al.
Published: (2022-08-01)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
by: Takayuki Kobayashi, MD, et al.
Published: (2023-07-01)

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
by: Zachary R. Schoepflin, MD, et al.
Published: (2023-04-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report
by: Ji Eun Park, et al.
Published: (2022-04-01)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
by: Kazuhiro Noguchi, et al.
Published: (2023-02-01)

Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases
by: Shan Liao, et al.
Published: (2022-07-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01)

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01)

Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case
by: A. V. Sultanbaev, et al.
Published: (2020-12-01)